Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00605215 · ClinicalTrials.gov registry record · Phase 3
BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)
A Phase 3 study, sponsored by Teva Branded Pharmaceutical Products R&D.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,331
- Enrollment target
NCT00605215 is a Phase 3 study that has completed, run by Teva Branded Pharmaceutical Products R&D. The registered enrollment target is 1,331 participants.
The verdict
NCT00605215, a Phase 3 study, has completed, sponsored by Teva Branded Pharmaceutical Products R&D.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,331 participants
- Enrollment target
Study Summary
The study aims to compare the effect of daily oral treatment of laquinimod capsules 0.6 milligrams (mg) with the effect of placebo capsules (capsules that contain no active medication) as well as with the effect of an existing Multiple Sclerosis (MS) injectable drug: Interferon β-1a (Avonex®).
Interventions
- DRUG Placebo
- DRUG Laquinimod
- DRUG Avonex®
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,331 participants |
| Start Date | 2008-04-24 |
| Est. Completion | 2011-06-10 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00605215
The ClinicalTrials.gov registry entry for NCT00605215 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 1,331 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Teva Branded Pharmaceutical Products R&D, which has 167 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT00605215 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00605215 about?
NCT00605215 is a clinical study titled "BRAVO Study: Laquinimod Double-blind Placebo-controlled Study in Participants With Relapsing-Remitting Multiple Sclerosis (RRMS) With a Rater Blinded Reference Arm of Interferon β-1a (Avonex®)". The study aims to compare the effect of daily oral treatment of laquinimod capsules 0.6 milligrams (mg) with the effect of placebo capsules (capsules that contain no active medication) as well as with the effect of an existing Multiple Sclerosis (MS) injectable drug: Interferon β-1a (Avonex®).
What is the current status of trial NCT00605215?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,331 participants. The study started on 2008-04-24. Estimated completion is 2011-06-10.
What interventions are being tested in trial NCT00605215?
The interventions under investigation include: Placebo (DRUG), Laquinimod (DRUG), Avonex® (DRUG).
Who is sponsoring clinical trial NCT00605215?
This trial is sponsored by Teva Branded Pharmaceutical Products R&D, which has 167 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.